Advertisement

International Cancer Conference Journal

, Volume 6, Issue 2, pp 60–64 | Cite as

Five-year survival of Advanced Esophagogastric junction cancer with achieved by complete response preoperative S-1 + CDDP combination therapy and surgical resection

  • Yoshikazu Kanazawa
  • Itsuo Fujita
  • Daisuke Kakinuma
  • Hitoshi Kanno
  • Hiroki Arai
  • Takeshi Matsutani
  • Nobutoshi Hagiwara
  • Tsutomu Nomura
  • Shunji Kato
  • Zenya Naito
  • Eiji Uchida
Case report

Abstract

No clear consensus has been reached about the appropriate chemotherapy and/or surgery for esophagogastric junction cancer (EGJ) cancer, and no recommendations have been established. However, it is hoped that treatment of advanced gastric cancer with preoperative chemotherapy will be useful, in that it will result in down staging, increased resection rate due to tumor contraction, and avoidance of the need for multi-organ resection, and that it will thus contribute to improved prognosis. Numerous clinical studies have been carried out to date on treatment of advanced gastric cancer with multi-drug combination chemotherapy, with S-1, a pyrimidine-fluoride-based anti-tumor agent, as the principal component, and favorable results have been achieved. The present report is about a 66-year-old male who was diagnosed as having Siewert type II, stage IIIB EGJ cancer, and whose bulky tumor was treated with S-1 + CDDP (SP) preoperative chemotherapy and total gastrectomy, with the aim of achieving preoperative tumor contraction. The outcome was achievement of histological complete response, and the patient has now survived for 5 years since surgery.

Keywords

Esophagogastric junction cancer S-1 + CDDP Neoadjuvant chemotherapy 5-Year survival Perioperative chemotherapy 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical.

Informed consent

Informed consent was obtained from the patient for the publication of this case presentation and accompanying images.

References

  1. 1.
    HiMattew F, Thomas L et al (2013) Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Elsevier Inc. Semin Radiat Oncol 23:3–9CrossRefGoogle Scholar
  2. 2.
    Nakamura T, Ide H, Eguchi R et.al (2002) Adenocarcinoma of the esophagogastric junction: a summary of responses to a questionnaire on adenocarcinoma of the esophagus and the esophagogastric junction cancer in Japan. Diseases Esophagus 15, 219–225CrossRefGoogle Scholar
  3. 3.
    Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–112Google Scholar
  4. 4.
    Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216CrossRefGoogle Scholar
  5. 5.
    Sasako M, Sakuramoto S, katai H et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393CrossRefPubMedGoogle Scholar
  6. 6.
    Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma-2nd English edition-gastric. Cancer 1;10–24Google Scholar
  7. 7.
    Christoph S, Stephan G, Florian L et al (2010)Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol 28(35):5210–5218CrossRefGoogle Scholar
  8. 8.
    Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20CrossRefPubMedGoogle Scholar
  9. 9.
    Yoshikawa T, Tanabe K, Nishikawa K et al (2014) Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. Ann Surg Oncol 21(1):213–219CrossRefPubMedGoogle Scholar
  10. 10.
    Iwasaki Y, Sasako M, Yamamoto S et al (2013) Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol 107:741–745CrossRefPubMedGoogle Scholar
  11. 11.
    Koizumi W, Narahara H, Hara T et al (2009) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221CrossRefGoogle Scholar

Copyright information

© The Japan Society of Clinical Oncology 2017

Authors and Affiliations

  • Yoshikazu Kanazawa
    • 1
  • Itsuo Fujita
    • 1
  • Daisuke Kakinuma
    • 1
  • Hitoshi Kanno
    • 1
  • Hiroki Arai
    • 1
  • Takeshi Matsutani
    • 1
  • Nobutoshi Hagiwara
    • 1
  • Tsutomu Nomura
    • 1
  • Shunji Kato
    • 1
  • Zenya Naito
    • 2
  • Eiji Uchida
    • 1
  1. 1.Department of Gastrointestinal and Hepatobiliary-Pancreatic SurgeryNippon Medical SchoolTokyoJapan
  2. 2.Department of PathologyNippon Medical SchoolTokyoJapan

Personalised recommendations